In a Canadian dispute for an antiviral product, CRA was retained to evaluate lost unit sales and lost profits suffered by a branded company from the allegedly improper sale of generic product in violation of a settlement agreement. At issue was the impact of the generic manufacturer flooding the market with product for a brief window of time before removing its product from the market and the effect on branded sales over time.
Smallest saleable patent-practicing unit in life sciences disputes
In this article titled “Smallest saleable patent-practicing unit in life sciences disputes,” author Erin McDermott examines methods for calculating damages in...